Intercept Pharmaceuticals Stock News

NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

Our Motley Fool roundtable likes Intercept Pharma, Viking Therapeutics, and Vir Bio.

In last trading session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) saw 0.68 million shares changing hands with its beta currently measuring 1.38. Company’s recent per share price level of $15.31 trading at $0.46 or 3.10% at ring of the bell on the day assigns it a market valuation of $420.41M. That closing price of ICPT’s stock is … Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) 24.23% Above Its 52-Week Low, How Long Will It Keep Rising? Read More »

Select analysts and investment banks believe these little-known companies can skyrocket.

Select analysts and investment banks believe these little-known companies can skyrocket.

Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.

Intercept Pharmaceuticals Inc (ICPT) shares closed today 12.2% higher than it did at the end of yesterday. The stock is currently down 7.9% year-to-date, down 51.8% over the past 12 months, and down 85.8% over the past five years. Today, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.9%. Trading Activity Shares traded as high as $17.06 and as low as $14.45 this week.Shares closed 56.8% below its 52-week high and 45.1% above its 52-week low.Trading volume this week was 21.6% higher than the 10-day average and 1.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 480.6% The company's stock price performance over the past 12 months lags the peer average by -953.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

B. Riley upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Neutral with a price target of $30, up from $25.  Analyst Mayank Mamtani sees a "catalyst rich" 1H of 2022 for the Compa

This could be a very exciting year for these drugmakers.

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.